[go: up one dir, main page]

WO2025188662A8 - Akt1 modulators - Google Patents

Akt1 modulators

Info

Publication number
WO2025188662A8
WO2025188662A8 PCT/US2025/018205 US2025018205W WO2025188662A8 WO 2025188662 A8 WO2025188662 A8 WO 2025188662A8 US 2025018205 W US2025018205 W US 2025018205W WO 2025188662 A8 WO2025188662 A8 WO 2025188662A8
Authority
WO
WIPO (PCT)
Prior art keywords
akt1
modulators
inhibitory compounds
inhibitors
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/018205
Other languages
French (fr)
Other versions
WO2025188662A1 (en
Inventor
Michael David Bartberger
Yi Fan
Eric Anthony MURPHY
Xuefeng Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterome Therapeutics Inc
Original Assignee
Alterome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alterome Therapeutics Inc filed Critical Alterome Therapeutics Inc
Publication of WO2025188662A1 publication Critical patent/WO2025188662A1/en
Publication of WO2025188662A8 publication Critical patent/WO2025188662A8/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
PCT/US2025/018205 2024-03-06 2025-03-03 Akt1 modulators Pending WO2025188662A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202463562149P 2024-03-06 2024-03-06
US63/562,149 2024-03-06
US202463570085P 2024-03-26 2024-03-26
US63/570,085 2024-03-26
US202463644336P 2024-05-08 2024-05-08
US63/644,336 2024-05-08

Publications (2)

Publication Number Publication Date
WO2025188662A1 WO2025188662A1 (en) 2025-09-12
WO2025188662A8 true WO2025188662A8 (en) 2025-10-02

Family

ID=96991507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/018205 Pending WO2025188662A1 (en) 2024-03-06 2025-03-03 Akt1 modulators

Country Status (1)

Country Link
WO (1) WO2025188662A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181947A1 (en) * 2009-12-30 2012-07-30 Arqule Inc Substituted imidazopyridinyl-aminopyridine compounds
CN117486876A (en) * 2020-09-30 2024-02-02 正大天晴药业集团股份有限公司 Compounds as inhibitors of Akt kinase
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof
WO2024054512A1 (en) * 2022-09-08 2024-03-14 Alterome Therapeutics, Inc. Akt1 modulators
WO2024102621A1 (en) * 2022-11-09 2024-05-16 Alterome Therapeutics, Inc. Akt1 modulators

Also Published As

Publication number Publication date
WO2025188662A1 (en) 2025-09-12

Similar Documents

Publication Publication Date Title
MX2025003515A (en) Akt1 modulators
PH12022551379A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
CR20240144A (en) Azetidine and pyrrolidine parp1 inhibitors and uses thereof
MX2025005941A (en) Modulators of tnf-î± activity
EP4596048A3 (en) Cd73 inhibitors
MX2024014262A (en) Inhibitors of parg
MX2024011254A (en) Nlrp3 modulators
EP4497438A3 (en) Tricyclic parp1 inhibitors and uses thereof
MX2022015410A (en) Inhibitors of fibroblast growth factor receptor kinases.
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
MX2025008092A (en) Inhibitors of kif18a and uses thereof
MX2022011576A (en) Nlrp3 modulators.
MX2024009105A (en) CDK4/6 KINASE INHIBITORS.
WO2022106897A3 (en) Methods and composition for kras modifications
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof
WO2023122260A3 (en) Inhibitors of sars-cov-2
WO2024099364A3 (en) Fused multicyclic compounds and their use as parp1 inhibitors
CL2024001756A1 (en) Inhibitors of met kinase
WO2023102162A8 (en) Novel hdac inhibitors and therapeutic use thereof
WO2020068950A8 (en) Hdac1,2 inhibitors
CR20240514A (en) Heteroaryl compounds for the treatment of pain
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25768202

Country of ref document: EP

Kind code of ref document: A1